Generation of Airway Epithelial Cell Air-Liquid Interface Cultures from Human Pluripotent Stem Cells
June 14th, 2022
5.2K views
Recent advances in human induced pluripotent stem cell differentiation protocols allow for the stepwise derivation of organ-specific cell types. Here, we provide detailed steps for the maintenance and expansion of iPSC-derived airway basal cells and their differentiation into a mucociliary epithelium in air-liquid interface cultures.
Overview
This protocol outlines the stepwise differentiation of human induced pluripotent stem cells (iPSCs) into functional airway epithelial cells. It details the maintenance and expansion of iPSC-derived airway basal cells and their subsequent differentiation into a mucociliary epithelium.
Key Study Components
Area of Science
- Stem Cell Biology
- Cell Differentiation
- Airway Biology
Background
- Human induced pluripotent stem cells (iPSCs) can be differentiated into various cell types.
- Airway epithelial cells are crucial for studying respiratory diseases.
- Traditional methods of obtaining primary airway cells are challenging.
- This protocol provides a reliable alternative for generating airway epithelial cells.
Purpose of Study
- To develop a protocol for generating functional airway epithelial cells from iPSCs.
- To facilitate the study of airway biology and related diseases.
- To simplify the process of culturing airway epithelial cells.
Methods Used
- Thawing and preparing 3D matrix and iPSC-derived cells.
- Centrifugation and resuspension of cells in Basal Cell Medium.
- Cell counting and sorting using specific antibodies.
- Monitoring cell confluence and transitioning to air-liquid interface cultures.
Main Results
- Successful generation of airway epithelial cells from iPSCs.
- Establishment of a reproducible culture system for airway cells.
- Demonstration of differentiation into a mucociliary epithelium.
- Potential applications in studying airway diseases.
Conclusions
- This protocol provides a robust method for generating airway epithelial cells.
- It offers a valuable tool for researchers studying airway biology.
- The method may enhance understanding of respiratory diseases.
Frequently Asked Questions
What are iPSC-derived airway basal cells?
iPSC-derived airway basal cells are cells generated from induced pluripotent stem cells that can differentiate into airway epithelial cells.
How long does the differentiation process take?
The differentiation process typically takes several weeks, depending on the specific protocol steps.
What is the significance of using a 3D matrix?
The 3D matrix supports cell growth and mimics the natural environment of airway epithelial cells.
Can this protocol be adapted for other cell types?
While this protocol is specific to airway epithelial cells, similar methods may be adapted for other epithelial cell types.
What applications do these cells have in research?
These cells can be used to study respiratory diseases, drug responses, and the effects of environmental factors on airway biology.
Executive Industry Relevance
Generating airway epithelial cell air-liquid interface (ALI) cultures from human pluripotent stem cells enables scalable, patient-specific disease modeling for respiratory disorders. This approach overcomes the bottleneck of sourcing primary airway cells, supporting robust target validation and mechanistic de-risking in early respiratory drug discovery. The protocol's reproducibility and genetic fidelity position it as a foundational tool for portfolio-wide translational research in airway diseases.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of disease mechanisms in genetically defined airway epithelial systems.
- Supports functional validation of targets implicated in cystic fibrosis, PCD, and other airway diseases.
- Facilitates mechanistic de-risking by recapitulating patient-specific epithelial defects in vitro.
- Provides a renewable source of disease-relevant cells for hypothesis-driven studies.
Screening & Assay Development
- Delivers standardized, reproducible ALI cultures for quantitative functional assays.
- Enables high-content screening of compounds affecting epithelial barrier integrity, cilia function, and mucus production.
- Supports assay development for CFTR-mediated chloride transport and ciliary motility endpoints.
- Allows for scalable preparation of validated biological systems for downstream workflows.
Translational & Preclinical Research
- Aligns in vitro disease models with patient genotypes for translational biomarker discovery.
- Enables continuity from discovery through preclinical validation using patient-derived cells.
- Supports risk-adjusted advancement decisions by modeling disease-relevant phenotypes.
- Provides predictive confidence for therapeutic efficacy in genetically diverse populations.
Pipeline & Workflow Integration
This protocol integrates into the discovery-to-preclinical continuum by enabling the generation of patient-specific airway epithelial models for target validation, assay development, and translational research.
- Discovery Biology: Supports hypothesis testing and mechanistic studies in genetically defined airway systems.
- Screening: Provides reproducible ALI cultures for quantitative assessment of epithelial function and drug response.
- Analytics: Enables measurement of TEER, cilia motility, and mucus secretion for comparative analysis.
- Translational Research: Bridges discovery and preclinical validation with disease-relevant, patient-derived models.
- Enterprise Reuse: Establishes a reusable platform for modeling diverse airway diseases across the portfolio.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in airway disease research.
- Operational Value: Standardizes cell sourcing and culture conditions for reproducibility and scalability.
- Strategic Value: Improves go/no-go decisions and capital efficiency by enabling robust in vitro validation.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory programs.
Implementation Considerations
- Requires expertise in stem cell culture, differentiation, and flow cytometry for cell sorting.
- Needs access to specialized instrumentation for ALI culture and functional readouts.
- Demands cross-team standardization of protocols for reproducibility across sites.
- Adaptation may be needed for different disease genotypes or model systems.
- Limitations include the need for careful quality control of differentiation and functional endpoints.
Biopharma FAQs
Why does null hypothesis testing matter for ALI culture target validation?
Null hypothesis testing in ALI cultures enables objective assessment of whether observed functional differences, such as TEER or cilia motility, are statistically significant between disease and control models. This rigor is essential for validating airway disease targets and reducing false positives in early discovery. Reliable statistical analysis underpins confidence in mechanistic findings and downstream portfolio decisions.
How does independent variable isolation fit the iPSC-derived airway workflow?
Isolating independent variables, such as genetic background or specific differentiation conditions, allows researchers to attribute observed phenotypes directly to the variable of interest. In the iPSC-derived airway workflow, this supports mechanistic de-risking and clarifies the impact of disease mutations or interventions on epithelial function. Controlled variable isolation strengthens the predictive value of in vitro findings.
What do quantitative TEER and cilia motility measurements enable?
Quantitative measurements of TEER and cilia motility provide objective, reproducible endpoints for comparing epithelial barrier integrity and mucociliary function across experimental conditions. These outputs enable high-confidence assessment of disease phenotypes and therapeutic responses, supporting robust assay development and screening in respiratory drug discovery.
Why are replication requirements critical for cross-functional airway model use?
Replication ensures that ALI culture results are consistent and reproducible across different operators, laboratories, and experimental runs. This is vital for cross-functional collaboration, enabling reliable data sharing and integration into multi-site discovery and translational workflows. Standardized replication supports enterprise-wide adoption and confidence in model outputs.
Which statistical analysis capabilities are required before ALI model implementation?
Robust statistical analysis capabilities, including significance testing and variance assessment, are required to validate functional readouts such as TEER, cilia motility, and mucus secretion. These analyses ensure that observed differences are meaningful and support data-driven decisions for advancing airway models in the discovery pipeline.
Chapters in this video
0:05
Introduction
0:40
Thawing of Cryopreserved iPSC-Derived Airway Basal Cells (iBCs)
2:43
Dissociation of Spheroids and Expansion of iBCs in 3-D Culture
4:55
Evaluation and Purification of NGFR and iBCs
6:10
Generation of Mucociliary Air-Liquid Interface (ALI) Cultures
8:37
Cryopreservation of iBCs (Optional but Recommended)
9:15
Results: Induced Pluripotent Stem Cells for the Derivation of iBCs and ALI Cultures
10:16
Conclusion
